 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Lantheus Holdings, Inc. (LNTH) develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide.
Its principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow.
The company also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging (MPI) procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke.
In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions.
Further, the company offers Additionally, it is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; 18F LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function with positron emission tomography; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque.
The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies.
We featured this stock at $23, now that is at $20.35, we like it even better! Shares are heading higher in an upward trading channel that is supported by the stock's 50-day moving average (shown in brown). Higher share prices are expected for this stock.
52-Weeks Trading Range: $7.95 - $24.10
Entry Point: $20.35
Stop Loss: $19.50
Target Price: $23.00
LNTH closed at $22.60
